Management of Early Interstitial Lung Disease in Chronic Smokers
Initial Assessment and Diagnosis
- Systematic assessment and documentation of interstitial lung abnormalities (ILAs) or ILD should be performed in smokers undergoing lung cancer screening with chest CT, as recommended by the American Thoracic Society, with approximately 8% of smokers found to have ILAs/ILD when screened with chest CT 1, 2
- Early ILD in smokers is associated with increased respiratory symptoms, accelerated lung function decline, and higher mortality, according to the American Journal of Respiratory and Critical Care Medicine 3
- Baseline symptom assessment should include evaluation for cough and dyspnea on exertion, as suggested by the American College of Chest Physicians 4
Primary Intervention: Smoking Cessation
- Smoking cessation is the single most effective strategy for slowing progression of lung disease and should be the first-line intervention, as recommended by the European Respiratory Society and the American Thoracic Society 5, 6
- A combination of pharmacotherapy and behavioral support increases smoking cessation success rates, with options including nicotine replacement therapy, varenicline, and bupropion, as suggested by the American College of Chest Physicians 6
Monitoring and Follow-up
- Pulmonary function tests (PFTs) are essential for follow-up assessment, as recommended by the European Respiratory Society 5
- Short-term PFTs (within 3 months) and repeat HRCT (within 6 months) should be considered to determine the rate of progression, as suggested by the Autoimmunity Reviews 7
- Monitor for progression to progressive pulmonary fibrosis (PPF), which causes irreversible lung damage and increased mortality, as recommended by the Autoimmunity Reviews 8
Special Considerations
- Patients should receive influenza and pneumococcal vaccinations to reduce the risk of respiratory infections, as recommended by the American College of Chest Physicians 6